ME02798B - Protutijela protiv dkk-1" - Google Patents
Protutijela protiv dkk-1"Info
- Publication number
- ME02798B ME02798B MEP-2017-212A MEP21217A ME02798B ME 02798 B ME02798 B ME 02798B ME P21217 A MEP21217 A ME P21217A ME 02798 B ME02798 B ME 02798B
- Authority
- ME
- Montenegro
- Prior art keywords
- seq
- cancer
- dkk
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Spisak SEQ ID
Claims (8)
1. Ljudsko konstruirano protutijelo protiv DKK-1, ili njegov antigenski vežući fragment, koje sadrži varijabilno područje lakog lanca (LCVR) i varijabilno područje teškog lanca (HCVR), gdje LCVR sadrži CDR-e LCDR1, LCDR2, te LCDR3, a HCVR sadrži CDR-e HCDR1, HCDR2, te HCDR3, gdje je LCDR1 SEQ ID NO: 5, LCDR2 je SEQ ID NO: 8, LCDR3 je SEQ ID NO: 7, HCDR1 je SEQ ID NO: 1, HCDR2 je SEQ ID NO: 2, a HCDR3 je SEQ ID NO:4, naznačeno time što je namijenjeno upotrebi u liječenju raka.
2. Ljudsko konstruirano protutijelo protiv DKK-1, ili njegov antigenski vežući fragment, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što se rak bira između multiplog mijeloma, raka dojke, te raka velikih stanica pluća.
3. Ljudsko konstruirano protutijelo protiv DKK-1, namijenjeno upotrebi u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačeno time što LCVR ima aminokiselinski slijed sa SEQ ID NO: 14, a HCVR ima aminokiselinski slijed sa SEQ ID NO: 12.
4. Ljudsko konstruirano protutijelo protiv DKK-1, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što ljudsko konstruirano protutijelo protiv DKK-1 sadrži teški lanac koji ima aminokiselinski slijed sa SEQ ID NO: 18 i laki lanac koji ima aminokiselinski slijed sa SEQ ID NO: 20.
5. Ljudsko konstruirano protutijelo protiv DKK-1, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačeno time što sadrži dva laka lanca, gdje svaki laki lanac ima aminokiselinski slijed sa SEQ ID NO: 20, i dva teška lanca, gdje svaki teški lanac ima aminokiselinski slijed sa SEQ ID NO: 18.
6. Farmaceutski pripravak koji sadrži ljudsko konstruirano protutijelo protiv DKK-1, ili njegov antigenski vežući fragment, koje sadrži varijabilno područje lakog lanca (LCVR) i varijabilno područje teškog lanca (HCVR), gdje LCVR sadrži CDR-e LCDR1, LCDR2, te LCDR3, a HCVR sadrži CDR-e HCDR1, HCDR2, te HCDR3, gdje je LCDR1 SEQ ID NO: 5, LCDR2 je SEQ ID NO: 8, LCDR3 je SEQ ID NO: 7, HCDR1 je SEQ ID NO: 1, HCDR2 je SEQ ID NO: 2, a HCDR3 je SEQ ID NO:4, uz farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćnu tvar, naznačen time što je namijenjen upotrebi u liječenju raka.
7. Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 6 u liječenju raka, naznačen time što se rak bira između multiplog mijeloma, raka dojke, te raka velikih stanica pluća.
8. Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 6 i patentnim zahtjevom 7, naznačen time što dodatno može sadržavati druge terapijske sastojke.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16841109P | 2009-04-10 | 2009-04-10 | |
| PCT/US2010/030039 WO2010117980A1 (en) | 2009-04-10 | 2010-04-06 | Dkk-1 antibodies |
| EP10712681.5A EP2417158B9 (en) | 2009-04-10 | 2010-04-06 | Dkk-1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02798B true ME02798B (me) | 2018-01-20 |
Family
ID=42199718
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-98A ME03378B (me) | 2009-04-10 | 2010-04-06 | Protutijela protiv dkk-1 |
| MEP-2017-212A ME02798B (me) | 2009-04-10 | 2010-04-06 | Protutijela protiv dkk-1" |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-98A ME03378B (me) | 2009-04-10 | 2010-04-06 | Protutijela protiv dkk-1 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8148498B2 (me) |
| EP (3) | EP3514173B8 (me) |
| JP (1) | JP5759977B2 (me) |
| KR (3) | KR20110124364A (me) |
| CN (1) | CN102388065B (me) |
| AR (1) | AR075989A1 (me) |
| AU (1) | AU2010234611B2 (me) |
| BR (1) | BRPI1014157B1 (me) |
| CA (1) | CA2758252C (me) |
| CY (3) | CY1119399T1 (me) |
| DK (3) | DK3514173T3 (me) |
| EA (1) | EA021401B1 (me) |
| ES (3) | ES2644244T3 (me) |
| HR (3) | HRP20171400T1 (me) |
| HU (3) | HUE043904T2 (me) |
| IL (1) | IL214845A (me) |
| LT (3) | LT2417158T (me) |
| ME (2) | ME03378B (me) |
| MX (1) | MX2011010707A (me) |
| NZ (1) | NZ595011A (me) |
| PL (3) | PL2417158T3 (me) |
| PT (3) | PT3514173T (me) |
| RS (3) | RS56505B1 (me) |
| SG (1) | SG175244A1 (me) |
| SI (3) | SI2930184T1 (me) |
| TR (1) | TR201907261T4 (me) |
| TW (1) | TWI546079B (me) |
| UA (1) | UA103916C2 (me) |
| WO (1) | WO2010117980A1 (me) |
| ZA (1) | ZA201107256B (me) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010131185A1 (en) | 2009-05-12 | 2010-11-18 | Pfizer Inc. | Blocking anti-dkk-1 antibodies and their uses |
| NZ708033A (en) | 2012-12-10 | 2020-03-27 | Biogen Ma Inc | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
| ES2755031T3 (es) | 2015-05-18 | 2020-04-21 | Lilly Co Eli | Compuestos de anticuerpos biespecíficos ANTI-DKK-1-ANTI-RANKL |
| KR20180054639A (ko) * | 2015-08-28 | 2018-05-24 | 알렉터 엘엘씨 | 항-siglec-7 항체 및 이의 사용 방법 |
| SMT202200118T1 (it) * | 2015-11-03 | 2022-05-12 | Janssen Biotech Inc | Anticorpi che legano specificamente pd-1 e loro usi |
| WO2018081437A1 (en) | 2016-10-26 | 2018-05-03 | Leap Therapeutics, Inc. | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| KR20210030341A (ko) | 2018-06-08 | 2021-03-17 | 알렉터 엘엘씨 | 항-Siglec-7 항체 및 그의 사용 방법 |
| MX2021000306A (es) * | 2018-07-11 | 2021-09-08 | Momenta Pharmaceuticals Inc | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno y fc modificados genéticamente dirigidos a ctla-4. |
| CN112121147B (zh) * | 2019-06-24 | 2023-07-04 | 中国人民解放军海军特色医学中心 | 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体 |
| JP2022549156A (ja) | 2019-09-19 | 2022-11-24 | リープ セラピューティクス，インコーポレイテッド | 癌を治療するためのｄｋｋ－１阻害剤の使用 |
| KR20220131223A (ko) * | 2019-11-22 | 2022-09-27 | 리프 테라퓨틱스 인코포레이티드 | Dkk-1 억제제를 사용하여 암을 치료하는 방법 |
| KR102494042B1 (ko) * | 2020-11-20 | 2023-02-07 | 주식회사 하울바이오 | 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도 |
| CN112592402B (zh) * | 2020-12-02 | 2022-04-26 | 杭州奕安济世生物药业有限公司 | 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途 |
| AU2022216290A1 (en) * | 2021-02-05 | 2023-09-14 | Omeros Corporation | Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19 |
| JP2024533439A (ja) | 2021-09-10 | 2024-09-12 | リープ セラピューティクス，インコーポレイテッド | 併用療法 |
| US20250122271A1 (en) * | 2022-01-28 | 2025-04-17 | Shanghai Junshi Biosciences Co., Ltd. | Anti-dkk1 antibody, pharmaceutical composition thereof, and use thereof |
| JP2025523801A (ja) | 2022-07-12 | 2025-07-25 | リープ セラピューティクス，インコーポレイテッド | 併用療法 |
| CN116589590B (zh) * | 2023-03-21 | 2024-03-26 | 浙江大学 | 一种特异性抗异菌脲的单克隆抗体及其重组表达质粒 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69837085T3 (de) | 1997-04-16 | 2012-01-12 | Millennium Pharmaceuticals, Inc. | Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen |
| DE19747418C1 (de) | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
| US7446181B2 (en) | 1998-01-15 | 2008-11-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind human Dickkopf-1 proteins |
| EP1490386B1 (en) | 1998-03-10 | 2008-08-13 | Genentech, Inc. | Novel polypeptide and nucleic acids encoding the same |
| EP1572987A4 (en) | 2000-02-03 | 2005-11-30 | Nuvelo Inc | NUCLEIC ACIDS AND POLYPEPTIDES |
| EP2280030A3 (en) | 2001-04-10 | 2011-06-15 | Agensys, Inc. | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
| US20040038860A1 (en) | 2002-05-17 | 2004-02-26 | Allen Kristina M. | Reagents and methods for modulating dkk-mediated interactions |
| JP2005512508A (ja) | 2001-05-17 | 2005-05-12 | ゲノム セラピューティックス コーポレーション | Ｄｋｋ媒介性相互作用を変調する試薬および方法 |
| JP2005512557A (ja) | 2001-11-07 | 2005-05-12 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー | 遺伝子発現プロファイリングに基づく多発性骨髄腫の診断、予後、および治療標的候補の同定 |
| US7308364B2 (en) | 2001-11-07 | 2007-12-11 | The University Of Arkansas For Medical Sciences | Diagnosis of multiple myeloma on gene expression profiling |
| US7371736B2 (en) | 2001-11-07 | 2008-05-13 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss |
| US7642238B2 (en) * | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
| US20050084494A1 (en) | 2003-05-21 | 2005-04-21 | Darwin Prockop | Inhibitors of Dkk-1 |
| JP2007525953A (ja) | 2003-06-06 | 2007-09-13 | ワイス | 骨リモデリングを調節する物質を同定するための方法および材料、ならびにそれによって同定された物質 |
| MX2007001221A (es) | 2004-08-04 | 2007-03-23 | Amgen Inc | Anticuerpos para proteina dickkopf-1 (dkk-1). |
| AR060017A1 (es) * | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
| WO2008097510A1 (en) * | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Antibodies specific for dkk-1 |
| WO2010129752A1 (en) * | 2009-05-07 | 2010-11-11 | Novartis Ag | Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both |
-
2010
- 2010-03-29 AR ARP100101019A patent/AR075989A1/es active IP Right Grant
- 2010-04-02 TW TW099110438A patent/TWI546079B/zh active
- 2010-04-06 HU HUE15159780A patent/HUE043904T2/hu unknown
- 2010-04-06 CA CA2758252A patent/CA2758252C/en active Active
- 2010-04-06 PT PT191565092T patent/PT3514173T/pt unknown
- 2010-04-06 DK DK19156509.2T patent/DK3514173T3/da active
- 2010-04-06 LT LTEP10712681.5T patent/LT2417158T/lt unknown
- 2010-04-06 TR TR2019/07261T patent/TR201907261T4/tr unknown
- 2010-04-06 PL PL10712681T patent/PL2417158T3/pl unknown
- 2010-04-06 RS RS20170959A patent/RS56505B1/sr unknown
- 2010-04-06 PL PL15159780T patent/PL2930184T3/pl unknown
- 2010-04-06 WO PCT/US2010/030039 patent/WO2010117980A1/en not_active Ceased
- 2010-04-06 HU HUE10712681A patent/HUE034625T2/en unknown
- 2010-04-06 US US12/754,637 patent/US8148498B2/en active Active
- 2010-04-06 SI SI201031877T patent/SI2930184T1/sl unknown
- 2010-04-06 SG SG2011075579A patent/SG175244A1/en unknown
- 2010-04-06 ES ES10712681.5T patent/ES2644244T3/es active Active
- 2010-04-06 BR BRPI1014157-0A patent/BRPI1014157B1/pt active IP Right Grant
- 2010-04-06 PT PT15159780T patent/PT2930184T/pt unknown
- 2010-04-06 SI SI201032080T patent/SI3514173T1/sl unknown
- 2010-04-06 KR KR1020117023571A patent/KR20110124364A/ko not_active Ceased
- 2010-04-06 EP EP19156509.2A patent/EP3514173B8/en active Active
- 2010-04-06 CN CN201080015994.4A patent/CN102388065B/zh active Active
- 2010-04-06 EP EP10712681.5A patent/EP2417158B9/en active Active
- 2010-04-06 HR HRP20171400TT patent/HRP20171400T1/hr unknown
- 2010-04-06 LT LTEP15159780.4T patent/LT2930184T/lt unknown
- 2010-04-06 LT LTEP19156509.2T patent/LT3514173T/lt unknown
- 2010-04-06 KR KR1020147005305A patent/KR101461362B1/ko active Active
- 2010-04-06 KR KR1020147018130A patent/KR20140090273A/ko not_active Ceased
- 2010-04-06 PL PL19156509T patent/PL3514173T3/pl unknown
- 2010-04-06 MX MX2011010707A patent/MX2011010707A/es active IP Right Grant
- 2010-04-06 AU AU2010234611A patent/AU2010234611B2/en active Active
- 2010-04-06 ME MEP-2019-98A patent/ME03378B/me unknown
- 2010-04-06 UA UAA201111272A patent/UA103916C2/ru unknown
- 2010-04-06 EP EP15159780.4A patent/EP2930184B1/en active Active
- 2010-04-06 DK DK15159780.4T patent/DK2930184T3/da active
- 2010-04-06 RS RS20190470A patent/RS58612B1/sr unknown
- 2010-04-06 SI SI201031526T patent/SI2417158T1/sl unknown
- 2010-04-06 HU HUE19156509A patent/HUE055376T2/hu unknown
- 2010-04-06 PT PT107126815T patent/PT2417158T/pt unknown
- 2010-04-06 JP JP2012504760A patent/JP5759977B2/ja active Active
- 2010-04-06 EA EA201171237A patent/EA021401B1/ru not_active IP Right Cessation
- 2010-04-06 RS RS20210998A patent/RS62214B1/sr unknown
- 2010-04-06 DK DK10712681.5T patent/DK2417158T4/da active
- 2010-04-06 ES ES19156509T patent/ES2887176T3/es active Active
- 2010-04-06 ES ES15159780T patent/ES2728911T3/es active Active
- 2010-04-06 ME MEP-2017-212A patent/ME02798B/me unknown
- 2010-04-06 NZ NZ595011A patent/NZ595011A/xx unknown
-
2011
- 2011-08-25 IL IL214845A patent/IL214845A/en active IP Right Grant
- 2011-10-04 ZA ZA2011/07256A patent/ZA201107256B/en unknown
-
2017
- 2017-09-29 CY CY20171101022T patent/CY1119399T1/el unknown
-
2019
- 2019-04-03 HR HRP20190643TT patent/HRP20190643T1/hr unknown
- 2019-05-17 CY CY20191100531T patent/CY1121637T1/el unknown
-
2021
- 2021-08-06 CY CY20211100700T patent/CY1124412T1/el unknown
- 2021-08-20 HR HRP20211343TT patent/HRP20211343T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02798B (me) | Protutijela protiv dkk-1" | |
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| JP2012523417A5 (me) | ||
| HRP20160151T1 (hr) | PROTUTIJELA PROTIV N3pGlu-AMILOIDNOG BETA PEPTIDA I NJIHOVA UPOTREBA | |
| HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
| JP2013542194A5 (me) | ||
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| NZ592436A (en) | Treatment with anti-alpha2 integrin antibodies | |
| HRP20140108T1 (hr) | Protutijela protiv sklerostina | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| IL259036A (en) | asct2-specific binding molecules and their uses | |
| PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
| JP2015514110A5 (me) | ||
| RU2015110981A (ru) | Комбинации и их применение | |
| NZ598391A (en) | Anti-hepcidin antibodies and uses thereof | |
| NZ590863A (en) | Anti-hepcidin-25 selective antibodies and uses thereof | |
| RU2016138744A (ru) | Антитела, фармацевтические композиции и их применения | |
| PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
| RU2016122340A (ru) | Il-17a-связующий агент и способы его применения | |
| HRP20161587T1 (hr) | Protutijela protiv bmp-6 | |
| JP2020502198A5 (me) | ||
| HRP20211059T1 (hr) | Antitijela za il-17c |